Drug intelligence / Profile preview

TC091

Development stage: Preclinical
Lead developer: TiCARos Therapeutics
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

TC091 is a chimeric antigen receptor T-cell (CAR-T) therapy developed by Ticaros, designed to target solid tumors. It utilizes Ticaros' proprietary CLIP CAR (Clamping-based Immune Synapse Potentiating CAR) technology, which aims to enhance both tumor-killing capability and stability. The drug is currently in preclinical development, with an Investigational New Drug (IND) submission planned for July 2026, and is being developed for various solid tumor indications, including liver, gallbladder, and pancreatic cancers.

Targets

MUC1 (Mucin-1 Antigen)

Beyond the preview

Go deeper on TC091.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TC091.

Explore the full profile